ImmunityBio Inc. (NASDAQ:IBRX) is one of the best multibagger penny stocks to buy right now. On December 12, analysts at ...
The latest update is out from Astellas Pharma ( (JP:4503) ).
Misconceptions about lung cancer, such as the stigma of smoking, are addressed, highlighting that anyone with lungs can ...
Harvey Risch, an epidemiologist respected for his cancer research, promoted the use of hydroxychloroquine during the pandemic ...
“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of ...
Merck (MRK) just cleared an important clinical hurdle, reporting strong Phase 3 KEYNOTE B15 results showing that KEYTRUDA ...
Armed with new three-year data demonstrating the benefits of Anktiva in a specific patient subset, ImmunityBio is proving its bladder cancer med is still one to watch as it competes with heavy hitt | ...
Merck, Pfizer and Astellas, which in August reported similar results from a Phase 3 study of the combination in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based ...
US biotech ImmunityBio announced that treatment with Anktiva (nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) demonstrates efficacy at 12 and 36 months, including disease-free ...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced positive topline results from an interim analysis of the Phase 3 EV-304 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback